Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2026)

Acadia Pharmaceuticals' Gross Margin history runs 11 years deep, the most recent figure standing at 90.75% for Q1 2026.

• On a quarterly basis, Gross Margin fell 90.0% year-over-year to 90.75% in Q1 2026; TTM through Mar 2026 was 91.47%, a 57.0% decrease from a year earlier, with the FY2025 full-year figure at 91.69%, up 24.0% from the prior year.
• Gross Margin steadied at 90.75% in Q1 2026 per ACAD's latest filing, from 90.77% in the prior quarter.
• Across five years, Gross Margin topped out at 98.59% in Q1 2023 and bottomed at 88.85% in Q1 2024.
• The 5-year median for Gross Margin is 92.47% (2024), against an average of 93.79%.
• Across the five-year window, Gross Margin surged 645 bps in 2022 and plunged 974 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 98.23% in 2022, then retreated by 6 bps to 92.26% in 2023, then decreased by 1 bps to 91.6% in 2024, then fell by 1 bps to 90.77% in 2025, then declined by 0 bps to 90.75% in 2026.
• Per Business Quant, the three latest ACAD Gross Margin figures stand at 90.75% (Q1 2026), 90.77% (Q4 2025), and 92.23% (Q3 2025).